Heart Failure News and Research

RSS

Heart failure (HF) is a condition in which a problem with the structure or function of the heart impairs its ability to supply sufficient blood flow to meet the body's needs. It should not be confused with cardiac arrest or myocardial infarction.

Metformin can have protective effects on the heart

The widely used diabetes medicine metformin can have protective effects on the heart, reveals a new study conducted at the Sahlgrenska Academy, at the University of Gothenburg, Sweden.

26 Mar 2012

Heart Failure Congress 2012 to take place from May 19-22

Four days of scientific sessions will be devoted to the latest advances and controversies in heart failure at this year's Heart Failure Congress 2012. The latest results from drugs and devices trials will be announced at the meeting.

21 Mar 2012

Two-year results from Boston Scientific's PROMUS Element trial to be presented at ACC 2012

Boston Scientific Corporation releases its schedule of product-related clinical research at the 61th Annual Scientific Session of the American College of Cardiology/i2 Summit, March 24-27 in Chicago.

21 Mar 2012

PATHS to examine needs of heart failure patients and primary caregivers

Less than 10 percent of people with heart failure receive supportive or palliative care beyond basic medical services, but a new research project, funded by a $1.7 million grant from the National Institute for Nursing Research to Penn State's School of Nursing, aims to change the situation.

20 Mar 2012

Epidemiologist examines effect of population aging on inpatient care

The effect of population aging on the number of admissions to hospital for inpatient treatment is examined by epidemiologist Enno Nowossadeck in the latest issue of Deutsches -rzteblatt International.

20 Mar 2012

FDA approves IDE for HeartWare 'ADVANCE' bridge-to-transplant clinical trial

HeartWare International, Inc., a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that the U.S. Food and Drug Administration has approved an IDE Supplement that allows HeartWare to enroll a fourth allotment, of 54 additional patients, in its "ADVANCE" bridge-to-transplant clinical trial under a Continued Access Protocol.

17 Mar 2012

Introducing art into nursing care improves stroke survivors' QOL

Stroke survivors who like art have a significantly higher quality of life than those who do not, according to new research. Patients who appreciated music, painting and theatre recovered better from their stroke than patients who did not.

16 Mar 2012

Abbott initiates enrollment in two HUMIRA Phase 3 trials for moderate to severe HS

Abbott today announced the initiation of two Phase 3 clinical trials designed to evaluate the safety and efficacy of an investigational use of HUMIRA (adalimumab) in adult patients with moderate to severe hidradenitis suppurativa.

16 Mar 2012

JAMA study: Higher spending = better quality in Canadian hospitals

Canadian hospitals that spent the most on patient care may be getting a bigger bang for their buck than their U.S. counterparts, researchers suggested. A study reported in the Journal of the American Medical Association compared patient results between Canadian hospitals that spent more on care, and those that spent less.

15 Mar 2012

Higher spending on effective procedures and services leads to better patient outcomes

Among hospitals in Ontario, Canada, those with higher levels of spending, which included higher intensity nursing and greater use of specialists and procedures, had an associated lower rate of deaths, hospital readmissions, and better quality of care for severely ill hospitalized patients, according to a study in the March 14 issue of JAMA.

14 Mar 2012

Electronics Letters publishes special supplement on Semiconductors in Personalised Medicine

Electronics Letters, renowned for its short, high quality international research papers at the cutting edge of technology, has now embraced Semiconductors in Personalised Medicine in its latest special supplement, available FREE online www.theiet.org/el-special.

14 Mar 2012

Modified Citrus Pectin binds and blocks harmful effects of Galectin-3

Galectin-3 sounds like a planet out of "Star Trek," but it can be much more ominous. Recently, distinguished integrative physician Isaac Eliaz, M.D., presented breakthrough research demonstrating that the protein Galectin-3 is an active biomarker for numerous life-threatening diseases. Even more importantly, Dr. Eliaz showed how Modified Citrus Pectin (MCP) binds and blocks Galectin-3 throughout the body.

14 Mar 2012

Scientists track genetic pathway of prostate cancer in new approach to drug discovery

Tracking the genetic pathway of a disease offers a powerful, new approach to drug discovery, according to scientists at the University of California, San Diego School of Medicine who used the approach to uncover a potential treatment for prostate cancer, using a drug currently marketed for congestive heart failure. Their findings are published in the current online issue of the Proceedings of the National Academy of Sciences.

14 Mar 2012

New recovery protocol treats heart failure patients with LVADs

Some patients with advanced heart failure caused by cardiomyopathy, the deterioration of function of the heart muscle, are benefitting from a new recovery protocol at the University of Louisville and Jewish Hospital, a part of KentuckyOne Health.

13 Mar 2012

MEDVAMC initiates Aeterna Zentaris' AEZS-130 Phase 2A trial in cancer cachexia

Aeterna Zentaris Inc. today announced that the Michael E. DeBakey Veterans Affairs Medical Center, in Houston, Texas, has initiated a Phase 2A trial assessing the safety and efficacy of repeated doses of the Company's ghrelin agonist, AEZS-130 (macimorelin), in patients with cancer cachexia.

9 Mar 2012

Women with chronic heart failure survive longer than their male counterparts

Women with chronic heart failure survive longer than their male counterparts, according to a large analysis of studies comprising data on more than 40,000 subjects. The analysis represents the largest assessment of gender and mortality risk in heart failure - and provides evidence which many randomised trials have failed to do because they have been dominated by male patients.

8 Mar 2012

New minimally invasive procedure can treat resistant hypertension

A radically different approach to treating high blood pressure - using a minimally invasive procedure- is being evaluated as part of a Pivotal Phase III 90-site national trial that includes The Carl H. and Edyth Lindner Center for Research and Education at The Christ Hospital.

8 Mar 2012

Lilly, Boehringer Ingelheim announce availability of Jentadueto tablets

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company today announced Jentadueto (linagliptin/metformin hydrochloride) tablets are now available by prescription in many leading chain and independent pharmacies across the U.S.

8 Mar 2012

Ivabradine could save thousands of heart failure patients

Researchers behind a major trial of Procoralan believe the pill could save 10,000 lives a year in Britain alone. Ivabradine works by slowing the beating of the heart, helping it to pump blood more efficiently.

7 Mar 2012

Nitrogen balance occurs with a precise 24-hour rhythm in mammals

Researchers at Case Western Reserve University School of Medicine demonstrated that nitrogen balance, the process of utilizing amino acids and disposing of their toxic byproducts, occurs with a precise 24-hour rhythm - also known as circadian rhythm - in mammals. Disruption of this cycle has a direct impact on survival of organisms, and may predispose one to life altering diseases including diabetes and cardiovascular disease.

7 Mar 2012